Trial Profile
Efficacy of Sunitinib 4:2 versus 2:1 regimen in patient with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Apr 2018 New trial record
- 07 Mar 2018 Results presented at the 16th International Congress on Targeted Anticancer Therapies.